Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 22, 2021
|
| In: |
JCO precision oncology
Year: 2021, Jahrgang: 5, Pages: 687-694 |
| ISSN: | 2473-4284 |
| DOI: | 10.1200/PO.20.00278 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/PO.20.00278 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/PO.20.00278 
|
| Verfasserangaben: | Dorothea Hanf, MD; Christoph Heining, MD; Karin Laaber, MSc; Heiner Nebelung, MD; Sebastian Uhrig, MSc; Barbara Hutter, PhD; Arne Jahn, MD; Daniela Richter, PhD; Daniela Aust, MD; Friederike Herbst, PhD; Stefan Fröhling, MD; Hanno Glimm, MD; and Gunnar Folprecht, MD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1838871152 | ||
| 003 | DE-627 | ||
| 005 | 20240807083057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/PO.20.00278 |2 doi | |
| 035 | |a (DE-627)1838871152 | ||
| 035 | |a (DE-599)KXP1838871152 | ||
| 035 | |a (OCoLC)1389537859 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hanf, Dorothea |d 1992- |e VerfasserIn |0 (DE-588)1204448728 |0 (DE-627)1689752785 |4 aut | |
| 245 | 1 | 0 | |a Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation |c Dorothea Hanf, MD; Christoph Heining, MD; Karin Laaber, MSc; Heiner Nebelung, MD; Sebastian Uhrig, MSc; Barbara Hutter, PhD; Arne Jahn, MD; Daniela Richter, PhD; Daniela Aust, MD; Friederike Herbst, PhD; Stefan Fröhling, MD; Hanno Glimm, MD; and Gunnar Folprecht, MD |
| 246 | 3 | 3 | |a Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3 G623R solvent-front mutation |
| 264 | 1 | |c April 22, 2021 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Text ist "G623R" hochgestellt | ||
| 500 | |a Gesehen am 10.03.2023 | ||
| 700 | 1 | |a Heining, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Laaber, Karin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nebelung, Heiner |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uhrig, Sebastian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hutter, Barbara |e VerfasserIn |0 (DE-588)14009752X |0 (DE-627)61602293X |0 (DE-576)314588760 |4 aut | |
| 700 | 1 | |a Jahn, Arne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Richter, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Aust, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herbst, Friederike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fröhling, Stefan |d 1969- |e VerfasserIn |0 (DE-588)120890046 |0 (DE-627)080950302 |0 (DE-576)188733930 |4 aut | |
| 700 | 1 | |a Glimm, Hanno |e VerfasserIn |4 aut | |
| 700 | 1 | |a Folprecht, Gunnar |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO precision oncology |d Alexandria, VA : American Society of Clinical Oncology, 2017 |g 5(2021), Seite 687-694 |h Online-Ressource |w (DE-627)1067396667 |w (DE-600)2964799-X |w (DE-576)518266486 |x 2473-4284 |7 nnas |a Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation |
| 773 | 1 | 8 | |g volume:5 |g year:2021 |g pages:687-694 |g extent:8 |a Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation |
| 856 | 4 | 0 | |u https://doi.org/10.1200/PO.20.00278 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/PO.20.00278 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230310 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 120890046 |a Fröhling, Stefan |m 120890046:Fröhling, Stefan |d 50000 |e 50000PF120890046 |k 0/50000/ |p 11 | ||
| 998 | |g 14009752X |a Hutter, Barbara |m 14009752X:Hutter, Barbara |d 50000 |e 50000PH14009752X |k 0/50000/ |p 6 | ||
| 999 | |a KXP-PPN1838871152 |e 4287009835 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"titleAlt":[{"title":"Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3 G623R solvent-front mutation"}],"language":["eng"],"note":["Im Text ist \"G623R\" hochgestellt","Gesehen am 10.03.2023"],"id":{"eki":["1838871152"],"doi":["10.1200/PO.20.00278"]},"physDesc":[{"extent":"8 S."}],"title":[{"title_sort":"Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation","title":"Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutation"}],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"April 22, 2021"}],"relHost":[{"disp":"Response to cabozantinib following acquired entrectinib resistance in a patient with ETV6-NTRK3 fusion-positive carcinoma harboring the NTRK3G623R solvent-front mutationJCO precision oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"JCO PO"}],"part":{"text":"5(2021), Seite 687-694","pages":"687-694","extent":"8","volume":"5","year":"2021"},"language":["eng"],"note":["Gesehen am 06.07.21"],"pubHistory":["Volume 1 (2017)-"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2473-4284"],"eki":["1067396667"],"zdb":["2964799-X"]},"title":[{"title_sort":"JCO precision oncology","subtitle":"an American Society of Clinical Oncology journal","title":"JCO precision oncology"}],"origin":[{"dateIssuedKey":"2017","publisherPlace":"Alexandria, VA","publisher":"American Society of Clinical Oncology","dateIssuedDisp":"2017-"}],"recId":"1067396667"}],"name":{"displayForm":["Dorothea Hanf, MD; Christoph Heining, MD; Karin Laaber, MSc; Heiner Nebelung, MD; Sebastian Uhrig, MSc; Barbara Hutter, PhD; Arne Jahn, MD; Daniela Richter, PhD; Daniela Aust, MD; Friederike Herbst, PhD; Stefan Fröhling, MD; Hanno Glimm, MD; and Gunnar Folprecht, MD"]},"person":[{"given":"Dorothea","display":"Hanf, Dorothea","role":"aut","family":"Hanf"},{"role":"aut","family":"Heining","display":"Heining, Christoph","given":"Christoph"},{"display":"Laaber, Karin","given":"Karin","role":"aut","family":"Laaber"},{"given":"Heiner","display":"Nebelung, Heiner","family":"Nebelung","role":"aut"},{"given":"Sebastian","display":"Uhrig, Sebastian","role":"aut","family":"Uhrig"},{"given":"Barbara","display":"Hutter, Barbara","family":"Hutter","role":"aut"},{"role":"aut","family":"Jahn","display":"Jahn, Arne","given":"Arne"},{"role":"aut","family":"Richter","display":"Richter, Daniela","given":"Daniela"},{"family":"Aust","role":"aut","given":"Daniela","display":"Aust, Daniela"},{"given":"Friederike","display":"Herbst, Friederike","role":"aut","family":"Herbst"},{"role":"aut","family":"Fröhling","display":"Fröhling, Stefan","given":"Stefan"},{"display":"Glimm, Hanno","given":"Hanno","family":"Glimm","role":"aut"},{"given":"Gunnar","display":"Folprecht, Gunnar","role":"aut","family":"Folprecht"}],"recId":"1838871152"} | ||
| SRT | |a HANFDOROTHRESPONSETO2220 | ||